Vir downsizes by 12%, will close St. Louis and Portland sites in 2024 to save $40M+ annually
As Vir Biotechnology expands beyond infectious diseases, where it made a mark in Ebola and the early days of Covid, the biotech will downsize and close two of its US sites to save $40 million or more annually, it said after Wednesday’s closing bell.
The San Francisco-based biotech, which developed a Covid antiviral with GSK and is still working on pandemic programs, will close its St. Louis site on April 15 and its Portland R&D facility on Sept. 30, a spokesperson told Endpoints News via email. It will continue running R&D work at its Bay Area and Bellinzona, Switzerland, sites.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
